Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

Hit the nail fairly and squarely on the head:

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
HinduKush Member Profile
Member Level 
Followed By 8
Posts 407
Boards Moderated 0
Alias Born 07/26/19
160x600 placeholder
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 6/1/2020 4:15:58 PM
Amarin Plans to Increase VASCEPA® (icosapent ethyl) Promotion and Education GlobeNewswire Inc. - 6/1/2020 7:00:10 AM
Amarin Supports Trial to Investigate the Effects of VASCEPA® (icosapent ethyl) in the Treatment of COVID-19 GlobeNewswire Inc. - 5/21/2020 4:05:10 PM
VASCEPA® (icosapent ethyl) Shows Significant Reduction in Coronary Revascularization, Including Coronary Stenting and Cardia... GlobeNewswire Inc. - 5/14/2020 2:50:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/8/2020 5:19:58 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 4/30/2020 6:39:17 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/30/2020 6:32:26 AM
Amarin Reports First Quarter 2020 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 4/30/2020 5:00:10 AM
Amended Annual Report (10-k/a) Edgar (US Regulatory) - 4/29/2020 4:12:49 PM
Amarin to Report First Quarter 2020 Results and Host Conference Call on April 30, 2020 GlobeNewswire Inc. - 4/28/2020 7:00:10 AM
Cannabis? CBD? That's Old News, A New Sector Bull Run Has Begun InvestorsHub NewsWire - 4/16/2020 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/13/2020 4:37:32 PM
Amarin to Host Conference Call on April 13, 2020 to Provide Preliminary First Quarter 2020 Results and Operational Update GlobeNewswire Inc. - 4/8/2020 4:05:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/31/2020 9:23:01 AM
Amarin Highlights VASCEPA® (Icosapent Ethyl)-Related Data Presented at American College of Cardiology’s Annual Scientific ... GlobeNewswire Inc. - 3/31/2020 7:00:10 AM
Amarin Comments on Ruling in VASCEPA® ANDA Litigation GlobeNewswire Inc. - 3/30/2020 6:25:32 PM
Eicosapentaenoic Acid (EPA) Levels From VASCEPA® (Icosapent Ethyl) in REDUCE-IT® Strongly Correlated with Cardiovascular Ou... GlobeNewswire Inc. - 3/30/2020 11:45:10 AM
Pharmaceutical Firms Curtailing In-Person Sales Calls to Doctors Dow Jones News - 3/16/2020 2:29:00 PM
Eight Data Presentations Relevant to VASCEPA® (Icosapent Ethyl) Capsules and Persistent Cardiovascular Risk to be Presented ... GlobeNewswire Inc. - 3/16/2020 8:00:10 AM
Amarin Takes Proactive Steps to Support Public Health Priorities GlobeNewswire Inc. - 3/15/2020 1:56:22 PM
Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr) Edgar (US Regulatory) - 2/26/2020 5:24:33 PM
ALYI Trending VERY BULLISH at $0.004 with 1000% ROI Potential InvestorsHub NewsWire - 2/26/2020 8:58:36 AM
Annual Report (10-k) Edgar (US Regulatory) - 2/25/2020 4:11:55 PM
HinduKush Member Level  Saturday, 05/23/20 04:30:08 PM
Re: TastyTheElf post# 275770
Post # of 277701 
Hit the nail fairly and squarely on the head:
Quote:
The offsetting of secondary considerations is a clear, crazy error. And the sequencing of prima facie vs secondary may be in error, but there is a debate there. I would say, however, that the pure factual errors are SO grotesque here that even if the procedural errors weren't out there, there is STILL a very compelling case for reversal. The defendants were so far from presenting clear and compelling prima facie evidence that we shouldn't even have needed any secondary conditions (although we had them -- in spades).



Yes, which is why I am trying to dig up as much verifiable documented literature of the period aka peer reviewed published articles circa 2000-2008 that I can. This is the litmus test of a POSA's opinion...on which The Du-ster should have based her prima facie enunciation...turns out she gave up cerebrating and her thesis is a house of straw waiting for the wind of knowledge to blow it down with a puff. I am aware of the rules of what might or might not be admissible but that's Singer's job.
HK

PS Irregardless of the papers/documents cited in the pretrial and trial briefs, Toth et al did a piss poor job, IMHO, (under Covington guidance) on conveying with clarity the true state of lipid science circa Mori 2000 on cross examination, leave alone establishing a favorable scientific thread of thought in her excellency's mind, whilst allowing themselves to be cornered into utterances that were later misquoted out of context through legal maneuvering on her part in her infamous judgment.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist